Value of drugs must be clear

06/17/2013 | Forbes

Demonstrating the value of medicines in the face of existing drugs is the real challenge, and not whether these treatments are first-in-class or best-in-class, writes John LaMattina. Value can mean improved safety or better efficacy, but it must be made clear to payers, doctors and patients, LaMattina writes.

View Full Article in:

Forbes

Published in Brief: